Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-05-14 | STML | Stemline Therapeutics Inc | Hoberman Kenneth | COO | S - Sale | $14.27 | -25,817 | 729,879 | -3% | -$368,409 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Thomsen Jillian B. | SVP, Chief Accounting Officer | S - Sale | $31.37 | -1,928 | 164,463 | -1% | -$60,481 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $31.37 | -13,383 | 295,736 | -4% | -$419,825 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Nicholson John | SVP, COO | S - Sale | $31.37 | -4,077 | 166,578 | -2% | -$127,895 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Labrucherie Gil M | SVP, CFO | S - Sale | $31.37 | -3,767 | 127,935 | -3% | -$118,171 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Hora Maninder | SVP Pharma Dev, Mfg Ops | S - Sale | $31.37 | -2,449 | 94,694 | -3% | -$76,825 | ||||||
2019-05-16 | NKTR | Nektar Therapeutics | Doberstein Stephen K | SVP, Chief Scientific Officer | S - Sale | $31.37 | -3,461 | 95,913 | -3% | -$108,572 | ||||||
| D | 2019-05-15 | GWPH | Gw Pharmaceuticals Plc | Tovey Christopher J. | COO | S - Sale+OE | $15.01 | -1,200 | 2,503 | -32% | -$18,012 | |||||
| M | 2019-05-15 | FTSV | Forty Seven, Inc. | Majeti Ravindra | Dir | S - Sale | $16.02 | -4,311 | 1,421,400 | 0% | -$69,044 | |||||
2019-05-16 | SPPI | Spectrum Pharmaceuticals Inc | Turgeon Joseph W. | CEO, Pres | S - Sale | $8.53 | -22,702 | 449,217 | -5% | -$193,755 | ||||||
| M | 2019-02-15 | AGLE | Aeglea Biotherapeutics, Inc. | Quinn Anthony G. | Pres, CEO | P - Purchase | $6.75 | +18,713 | 295,146 | +7% | +$126,399 | |||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachdev Amit | EVP, CRO | S - Sale | $165.41 | -61 | 53,262 | 0% | -$10,090 | ||||||
| M | 2019-05-13 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | CEO | P - Purchase | $0.01 | +81,500 | 21,834,397 | 0% | +$1,037 | |||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Silva Paul M | SVP, Controller | S - Sale | $165.41 | -161 | 17,928 | -1% | -$26,631 | ||||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Parini Michael | EVP, CL, AO | S - Sale | $165.41 | -83 | 35,003 | 0% | -$13,729 | ||||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Kewalramani Reshma | EVP, CMO | S - Sale | $165.41 | -241 | 13,736 | -2% | -$39,864 | ||||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Arbuckle Stuart A | EVP\Chief Commercial Officer | S - Sale | $165.41 | -133 | 33,380 | 0% | -$22,000 | ||||||
2019-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Altshuler David | EVP, Global Research, CSO | S - Sale | $165.41 | -91 | 31,553 | 0% | -$15,052 | ||||||
| D | 2019-05-15 | ALNY | Alnylam Pharmaceuticals, Inc. | Maraganore John | CEO | S - Sale+OE | $70.00 | -49,457 | 193,092 | -20% | -$3,461,990 | |||||
2019-05-15 | COLL | Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Dir | S - Sale | $12.84 | -25,000 | 182,069 | -12% | -$321,042 | ||||||
2019-05-15 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, CFO, MD | S - Sale | $58.38 | -8,000 | 415,230 | -2% | -$467,017 | ||||||
2019-05-14 | CNAB | United Cannabis Corp | Verzura Tony | 10% | S - Sale | $0.25 | -200,000 | 11,735,885 | -2% | -$50,000 | ||||||
2019-05-15 | BSTC | Biospecifics Technologies Corp | Gitman Paul | Dir | S - Sale | $65.83 | -5,000 | 15,000 | -25% | -$329,150 | ||||||
| D | 2019-05-15 | RETA | Reata Pharmaceuticals Inc | Wilson Jason Douglas | CFO | S - Sale+OE | $89.91 | -4,000 | 0 | -100% | -$359,631 | |||||
| D | 2019-05-15 | CRMD | Cormedix Inc. | Dillione Janet | Dir | P - Purchase | $6.74 | +11,144 | 47,326 | +31% | +$75,111 | |||||
2019-05-16 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $2.02 | +100,000 | 215,841,633 | 0% | +$202,139 | ||||||
| M | 2019-05-15 | RTRX | Retrophin, Inc. | McFarlane Neil F. | COO | S - Sale | $18.25 | -1,968 | 26,988 | -7% | -$35,906 | |||||
| M | 2019-05-15 | RTRX | Retrophin, Inc. | Clague Laura | CFO | S - Sale | $18.25 | -2,500 | 13,500 | -16% | -$45,613 | |||||
| M | 2019-05-14 | RTRX | Retrophin, Inc. | Rote William E. | SVP, R, D | S - Sale | $17.77 | -1,625 | 18,185 | -8% | -$28,876 | |||||
| M | 2019-05-14 | RTRX | Retrophin, Inc. | Reed Elizabeth E | SVP, GC, Corporate Secretary | S - Sale | $17.73 | -1,050 | 19,508 | -5% | -$18,617 | |||||
| M | 2019-05-14 | RTRX | Retrophin, Inc. | Aselage Steve | Dir | S - Sale | $17.80 | -3,676 | 255,966 | -1% | -$65,451 | |||||
2019-05-15 | CTLT | Catalent, Inc. | Morel Donald E Jr | Dir | P - Purchase | $44.44 | +10,000 | 46,958 | +27% | +$444,400 | ||||||
| D | 2019-05-14 | URGN | Urogen Pharma Ltd. | Mullennix Stephen | COO | S - Sale+OE | $37.98 | -608 | 5,381 | -10% | -$23,092 | |||||
| M | 2019-05-14 | NERV | Minerva Neurosciences, Inc. | Index Venture Associates III Ltd | 10% | S - Sale | $6.66 | -134,828 | 4,474,361 | -3% | -$898,161 | |||||
| DM | 2019-05-14 | SVRA | Savara Inc | Hawkins Richard J | Dir | S - Sale+OE | $11.10 | -25,000 | 0 | -100% | -$277,622 | |||||
| D | 2019-05-16 | RGLS | Regulus Therapeutics Inc. | Hagan Joseph P | Pres, CEO | S - Sale+OE | $1.22 | -39,352 | 268,167 | -13% | -$47,966 | |||||
| D | 2019-05-15 | RGLS | Regulus Therapeutics Inc. | Chevallard Daniel R. | CFO | S - Sale+OE | $1.41 | -10,000 | 80,539 | -11% | -$14,089 | |||||
| D | 2019-05-15 | RGLS | Regulus Therapeutics Inc. | Aker Christopher Ray | SVP, GC | S - Sale+OE | $1.41 | -6,950 | 59,309 | -10% | -$9,796 | |||||
2019-05-15 | AMRX | Amneal Pharmaceuticals, Inc. | Bhadauria Pradeep | SVP, Chief Scientific Officer | P - Purchase | $8.48 | +7,000 | 7,500 | >999% | +$59,360 | ||||||
| D | 2019-05-14 | ZTS | Zoetis Inc. | Lewis Clinton A. Jr. | EVP | S - Sale+OE | $101.90 | -6,123 | 45,803 | -12% | -$623,934 | |||||
| A | 2019-05-03 | LLY | Lilly Eli & Co | Shaw Christi | SVP, Pres, Lilly Bio-Meds | S - Sale | $117.08 | -7,077 | 500 | -93% | -$828,575 | |||||
| D | 2019-05-14 | CERC | Cerecor Inc. | Pedder Simon | Exec COB of the Bd | P - Purchase | $5.06 | +6,000 | 6,000 | New | +$30,336 | |||||
2019-05-14 | LGND | Ligand Pharmaceuticals Inc | Aryeh Jason | Dir | P - Purchase | $112.51 | +250 | 115,987 | 0% | +$28,128 | ||||||
2019-05-16 | CLSN | Celsion Corp | Tardugno Michael H | COB, Pres, CEO | P - Purchase | $2.16 | +5,000 | 32,700 | +18% | +$10,810 | ||||||
2019-05-16 | CLSN | Celsion Corp | Martinez Alberto R Jr | Dir | P - Purchase | $2.15 | +4,000 | 24,000 | +20% | +$8,600 | ||||||
2019-05-15 | HRTX | Heron Therapeutics, Inc. /de/ | Christian Waage | Dir | P - Purchase | $18.04 | +1,400 | 1,400 | New | +$25,262 | ||||||
| D | 2019-05-15 | VTVT | Vtv Therapeutics Inc. | Perelman Ronald O | 10% | P - Purchase | $1.84 | +1,358,698 | 17,852,351 | +8% | +$2,500,004 | |||||
2019-05-15 | REGN | Regeneron Pharmaceuticals Inc | Goldstein Joseph L | Dir | S - Sale | $305.93 | -1,000 | 11,323 | -8% | -$305,930 | ||||||
| DM | 2019-05-13 | FGEN | Fibrogen Inc | Neff Thomas B | CEO | S - Sale+OE | $36.34 | -39,636 | 2,642,114 | -1% | -$1,440,554 | |||||
| D | 2019-05-13 | MRTX | Mirati Therapeutics, Inc. | Grey Michael G | Dir | S - Sale+OE | $65.30 | -5,760 | 1,340 | -81% | -$376,138 | |||||
| M | 2019-05-13 | VRCA | Verrica Pharmaceuticals Inc. | Davidson Matt | 10% | S - Sale | $9.11 | -6,973 | 2,719,119 | 0% | -$63,554 | |||||
2019-05-14 | ITCI | Intra-Cellular Therapies, Inc. | Alafi Christopher D | Dir | P - Purchase | $12.56 | +100,000 | 5,307,129 | +2% | +$1,256,350 | ||||||
| D | 2019-05-13 | NXTC | Nextcure, Inc. | Sofinnova Venture Partners Ix, L.P. | 10% | P - Purchase | $15.00 | +400,000 | 2,521,856 | +19% | +$6,000,000 | |||||
2019-05-14 | SAVA | Cassava Sciences Inc | Schoen Eric | CFO | P - Purchase | $1.06 | +10,000 | 10,000 | New | +$10,600 | ||||||
2019-05-13 | ELAN | Elanco Animal Health Inc | Bilbrey John P | Dir | P - Purchase | $32.39 | +7,750 | 10,533 | +278% | +$251,023 | ||||||
| M | 2019-05-13 | ANIP | Ani Pharmaceuticals Inc | Przybyl Arthur | Pres, CEO | S - Sale | $70.07 | -30,000 | 202,589 | -13% | -$2,102,177 | |||||
2019-05-13 | TXMD | Therapeuticsmd, Inc. | Collins Cooper C. | Dir | P - Purchase | $3.33 | +30,000 | 66,000 | +83% | +$99,870 | ||||||
2019-05-15 | ANIP | Ani Pharmaceuticals Inc | Haughey Thomas | Dir | P - Purchase | $69.30 | +2,500 | 6,291 | +66% | +$173,240 | ||||||
2019-05-14 | ANIP | Ani Pharmaceuticals Inc | Marken James G. | SVP Ops, Prod Dev | S - Sale | $70.31 | -4,917 | 70,137 | -7% | -$345,714 | ||||||
2019-05-15 | LCI | Lannett Co Inc | Farber Jeffrey | Dir | P - Purchase | $5.80 | +5,000 | 2,101,054 | 0% | +$29,000 | ||||||
| D | 2019-05-14 | RLMD | Relmada Therapeutics, Inc. | Kelly Paul Edward | Dir | P - Purchase | $1.50 | +100,000 | 488,483 | +26% | +$150,000 | |||||
| D | 2019-05-13 | REPH | Recro Pharma, Inc. | Henwood Geraldine | Pres, CEO | S - Sale+OE | $8.89 | -144,806 | 248,141 | -37% | -$1,287,296 | |||||
2019-05-13 | FLXN | Flexion Therapeutics Inc | Arkowitz David | CFO | P - Purchase | $11.99 | +4,000 | 86,924 | +5% | +$47,960 | ||||||
| D | 2019-05-14 | REGN | Regeneron Pharmaceuticals Inc | Stahl Neil | EVP Research, Development | S - Sale+OE | $305.74 | -9,853 | 44,681 | -18% | -$3,012,483 | |||||
2019-05-13 | BGNE | Beigene, Ltd. | Glazer Donald W. | Dir | S - Sale | $125.11 | -15,027 | 3,949,678 | 0% | -$1,880,028 | ||||||
| D | 2019-05-13 | MIST | Milestone Pharmaceuticals Inc. | Fonds De Solidarite Des Travailleurs Du Quebec | 10% | P - Purchase | $15.00 | +433,333 | 2,720,310 | +19% | +$6,499,995 | |||||
2019-05-13 | DRRX | Durect Corp | Saxe Jon S | Dir | P - Purchase | $0.71 | +9,600 | 122,810 | +8% | +$6,773 | ||||||
2019-05-14 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Millian Craig Stuart | Chief Commercial Officer | P - Purchase | $7.23 | +1,000 | 6,000 | +20% | +$7,227 | ||||||
2019-05-13 | AKRX | Akorn Inc | Rappuhn Terry Allison | Dir | P - Purchase | $4.03 | +10,000 | 68,198 | +17% | +$40,300 | ||||||
2019-05-13 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | P - Purchase | $21.44 | +4,650 | 657,748 | +1% | +$99,696 | ||||||
2019-05-14 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $2.00 | +1,000,000 | 215,741,633 | 0% | +$1,995,024 | ||||||
2019-05-14 | APVO | Aptevo Therapeutics Inc. | White Marvin L | Pres, CEO | P - Purchase | $0.78 | +10,000 | 213,603 | +5% | +$7,800 | ||||||
| D | 2019-05-10 | GWPH | Gw Pharmaceuticals Plc | Gangolli Julian S | Pres, North America | S - Sale+OE | $14.84 | -671,928 | 106,548 | -86% | -$9,973,283 | |||||
2019-05-14 | LGND | Ligand Pharmaceuticals Inc | Higgins John L | CEO | P - Purchase | $113.50 | +2,500 | 143,899 | +2% | +$283,750 | ||||||
| D | 2019-05-14 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale+OE | $112.92 | -2,500 | 25,542 | -9% | -$282,300 | |||||
| M | 2019-05-10 | CERC | Cerecor Inc. | Armistice Capital, LLC | Dir, 10% | P - Purchase | $4.97 | +20,000 | 36,938,570 | 0% | +$99,312 | |||||
| D | 2019-05-10 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | CEO | S - Sale+OE | $82.52 | -10,000 | 507,861 | -2% | -$825,193 | |||||
2019-05-13 | DRRX | Durect Corp | Saxe Jon S | Dir | P - Purchase | $0.70 | +40,400 | 85,400 | +90% | +$28,095 | ||||||
2019-05-14 | ICPT | Intercept Pharmaceuticals, Inc. | Benatti Luca | Dir | P - Purchase | $83.50 | +1,200 | 7,556 | +19% | +$100,200 | ||||||
2019-05-10 | XOMA | Xoma Corp | Van Ness W Denman | Dir | S - Sale | $14.71 | -130 | 9,945 | -1% | -$1,912 | ||||||
2019-05-13 | TXMD | Therapeuticsmd, Inc. | Thompson Tommy G | Dir | P - Purchase | $3.34 | +2,400 | 690,456 | 0% | +$8,016 | ||||||
2019-05-14 | SPPI | Spectrum Pharmaceuticals Inc | Riga Thomas J | EVP, COO, CCO | S - Sale | $8.82 | -2,388 | 266,133 | -1% | -$21,069 | ||||||
2019-05-14 | SPPI | Spectrum Pharmaceuticals Inc | McGahan Keith M | SVP, GC | S - Sale | $8.82 | -458 | 141,290 | 0% | -$4,041 | ||||||
| D | 2019-05-10 | BDSI | Biodelivery Sciences International Inc | Broadfin Healthcare Master Fund Ltd | Dir | S - Sale+OE | $5.00 | -1,800,000 | 4,281,943 | -30% | -$9,000,000 | |||||
| D | 2019-05-13 | MIST | Milestone Pharmaceuticals Inc. | Novo Holdings A/s | 10% | P - Purchase | $15.00 | +333,333 | 2,674,470 | +14% | +$4,999,995 | |||||
| D | 2019-05-13 | ZTS | Zoetis Inc. | Peck Kristin C | EVP | S - Sale+OE | $100.92 | -11,500 | 41,377 | -22% | -$1,160,580 | |||||
2019-05-10 | IRWD | Ironwood Pharmaceuticals Inc | McCourt Thomas A | Pres | S - Sale | $10.53 | -4,055 | 107,239 | -4% | -$42,699 | ||||||
2019-05-10 | IRWD | Ironwood Pharmaceuticals Inc | Gilbert Halley E | Chief Admin Officer, SVP | S - Sale | $10.53 | -4,055 | 238,240 | -2% | -$42,699 | ||||||
2019-05-10 | IRWD | Ironwood Pharmaceuticals Inc | Currie Mark G | Dir | S - Sale | $10.53 | -4,055 | 528,903 | -1% | -$42,699 | ||||||
2019-05-13 | YMAB | Y-Mabs Therapeutics, Inc. | Gad Thomas | Pres, COB | S - Sale | $20.61 | -6,000 | 1,964,557 | 0% | -$123,647 | ||||||
2019-05-10 | IRWD | Ironwood Pharmaceuticals Inc | Consylman Gina | SVP, CFO, Treasurer | S - Sale | $10.53 | -4,055 | 175,860 | -2% | -$42,699 | ||||||
2019-05-14 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Moran Sean F. | CFO | P - Purchase | $7.12 | +100 | 349,610 | 0% | +$712 | ||||||
| D | 2019-05-10 | PKTX | Protokinetix, Inc. | Guzzetta Michael Richard | CFO | P - Purchase | $0.12 | +2,500 | 69,987 | +4% | +$288 | |||||
2019-05-13 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO | P - Purchase | $6.99 | +995 | 64,185 | +2% | +$6,955 | ||||||
| D | 2019-05-13 | CRTX | Cortexyme, Inc. | Pfizer Inc | 10% | P - Purchase | $17.00 | +50,000 | 3,249,973 | +2% | +$850,000 | |||||
2019-05-13 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.99 | +200,000 | 214,741,633 | 0% | +$397,687 | ||||||
2019-05-13 | OPK | Opko Health, Inc. | Pfenniger Richard C Jr | Dir | P - Purchase | $2.05 | +50,000 | 220,000 | +29% | +$102,492 | ||||||
| D | 2019-05-13 | NXTC | Nextcure, Inc. | Shannon Timothy M | Dir | P - Purchase | $15.00 | +50,000 | 2,254,442 | +2% | +$750,000 | |||||
| D | 2019-05-13 | NXTC | Nextcure, Inc. | Khuong Chau Quang | Dir | P - Purchase | $15.00 | +350,000 | 2,711,013 | +15% | +$5,250,000 | |||||
| D | 2019-05-13 | NXTC | Nextcure, Inc. | Xu Stella | Dir | P - Purchase | $15.00 | +125,000 | 1,103,570 | +13% | +$1,875,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |